Scientific References
Identifying functional loss of ATM gene in patients with advanced cancer.
Patrick Glen Pilie et al. ASCO. 2020
Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity
Alexandra O, et al. Clinical Cancer Research. May 1 2020 DOI: 10.1158/1078-0432.CCR-20-0707
Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature. 2020; 578(7793):82–93. doi:10.1038/s41586-020-1969-6
Synthetic lethality as an engine for cancer drug target discovery.
Huang A, Garraway LA, Ashworth A, Weber B. Nat Rev Drug Discov. 2020;19(1):23–38
Wengner AM, Siemeister G, Lücking U, et al. Mol Cancer Ther. 2020;19(1):26–38.
CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.
Su D, Feng X, Colic M, et al. DNA Repair (Amst). 2020;87:102803.
A CRISPR Way to Identify Cancer Targets.
Hahn WC. N Engl J Med. 2019;380(25):2475–2477.
J S. De Bono et al. Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3007-3007
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
TA Knijnenburg et al. Cell Rep 23 (1), 239-254.e6. 2018
Zehir A, Benayed R, Shah RH, et al. Nat Med. 2017;23(6):703–713.
Synthetic lethality in lung cancer and translation to clinical therapies.
Leung AW, de Silva T, Bally MB, Lockwood WW. Mol Cancer. 2016;15(1):61. Published 2016 Sep 29.
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart T, Chandrashekhar M, Aregger M, et al. Cell. 2015;163(6):1515–1526.
The concept of synthetic lethality in the context of anticancer therapy.
Kaelin WG Jr. Nat Rev Cancer. 2005;5(9):689–698.
Global mapping of the yeast genetic interaction network.
Tong AH, Lesage G, Bader GD, et al. Science. 2004;303(5659):808–813.